

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF
HOUGHTON ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP03/11271

FILED: 10 OCTOBER 2003

U.S. APPLICATION NO:

35 USC §371 DATE:

FOR: USE OF IMATINIB (GLIVEC, STI-571) TO INHIBIT BREAST
CANCER RESISTANCE PROTEIN (BCRP)-MEDIATED
RESISTANCE TO THERAPEUTIC AGENTS

MS: Amendment
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 of the international application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references were cited in the international stage search report. Since these references are of record in the instant PCT application PCT/EP03/11271, copies are not enclosed herewith.

10/530618

07 APR 2005

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7898


Lydia T. McNally
Attorney for Applicants
Reg. No. 36,214

Date: *April 7, 2005*

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
ON 4/32/21
APPLICATION NO.
Not yet assigned
APPLICANT
HOUGHTON ET AL.
FILING DATE
Herewith

Sheet 1 of 2

10/530618

PCT/PTO 07 APR 2005

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM						<input type="checkbox"/>	<input type="checkbox"/>
	AN						<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AR	J. A. Fagin, "Perspective: Lessons learned from molecular genetic studies of thyroid cancer: Insights into pathogenesis and tumor-specific therapeutic targets," Endocrinology, Vol. 143(6), pp. 2025-2028 (2002)
AS	A. Levitzki, "Tyrosine kinases as targets for cancer therapy," European Journal of Cancer, Vol. 38, pp. S11-S18 (2002)
AT	B. Selle et al., "ABL-specific tyrosine kinase inhibitor imatinib as salvage therapy in a child with Philadelphia chromosome-positive acute mixed lineage leukemia (AMLL)," Leukemia, Vol. 16(7), pp. 1393-1395 (2002)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.

ON/4-32721A

APPLICATION NO.

Not yet assigned

APPLICANT

HOUGHTON ET AL.

FILING DATE

Herewith

10/27/93 30618
Sheet 2 of 2

Dec'd PCT/PTO 07 APR 2005

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	BA	5,521,184	5/28/96	Zimmermann			
	BB						
	BC						
	BD						
	BE						
	BF						
	BG						
	BH						
	BI						
	BJ						
	BK						
	BL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	BM	0 564 409	10/6/93	EP			<input type="checkbox"/>	<input type="checkbox"/>
	BN						<input type="checkbox"/>	<input type="checkbox"/>
	BO						<input type="checkbox"/>	<input type="checkbox"/>
	BP						<input type="checkbox"/>	<input type="checkbox"/>
	BQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	BR	R. Capdeville et al., "Imatinib: the first 3 years," European Journal of Cancer, Vol. 38, pp. S77-S82 (2002)
	BS	Y. Kano et al., "In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents," Blood Vol. 97(7), pp. 1999-2007 (2001)
	BT	J. Topaly et al., "Synergistic activity of STI571 with chemotherapeutic drugs and irradiation," Blood, Vol. 96(11), p. 736A (2000)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.